Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The FDA body mass index criteria for Wegovy are: Individual with BMI 30 kg/m (obesity) Individuals with BMI 27 kg/m (overweight) with at least one weight-related health condition, such as 2 diabetes mellitus, high blood pressure (hypertension), high cholesterol (hypercholesterolemia), and lipid levels (dyslipidemia)
GLP-1 therapies , including semaglutide or tirzepatide , are administered under the close supervision of our medical team, ensuring dosing levels align precisely with original FDA clinical trials.Patients also receive ongoing nutrition and lifestyle counseling , with access to their care team around the clock for guidance, support, and side-effect management
On communication, GLP-1 users are more intentional label readers than the average consumer messaging that aligns with their health priorities will build the trust that this cohort responds to
The peptides are administered with a very fine needle, similar to what's used for insulin, just under the skin in the abdomen
What to Expect Results vary depending on: Nutrition Exercise Sleep Hormonal balance Metabolic health Consistency Early Changes Some patients report: Better energy Improved motivation Reduced bloating Improved workout consistency 612 Weeks Possible changes may include: Reduction in stubborn fat Leaner appearance Better body composition Improved exercise tolerance Long-Term For longer-term body composition goals many patients combine AOD-9604 with: Resistance training Nutrition optimization Hormone therapy GLP-1 medications Peptide stacking strategies AOD-9604 FAQ What does AOD-9604 do
US$ 29.36
US$ 27.53
US$ 27.32
US$ 27.89
US$ 22.47
